Intellia Therapeutics Inc Strategic Collaboration to Develop Novel Genomic Medicines Transcript
Good morning, good afternoon, bon jour. Welcome to this webcast to discuss SparingVision's strategic collaboration with Intellia Therapeutics. My name is Nathalie Trepo, Director of Investor Relations and Communications at SparingVision.
Earlier today, Intellia Therapeutics and SparingVision issued a press release detailing the terms of the strategic collaboration we will discuss today. This press release is available on the News section of the SparingVision website. Following today's prepared remarks, we will open up the call for questions. We, therefore, kindly ask that you keep your questions for the Q&A session.
We would also like to remind you that this call is being recorded. A replay will be made available on the SparingVision website.
With that, I will turn it over to Stéphane Boissel, Chief Executive Officer of SparingVision.
Thank you, Nathalie. Good afternoon or good morning. I'm myself in California so it will be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
